TimeTeller® receives InnoRampUp funding to continue the development of an in vitro diagnostic technology to profile circadian rhythms

TimeTeller® has been selected for funding by the InnoRampUp program by the IFB Hamburg in 2023. The funding will allow TimeTeller® to continue developing an in vitro diagnostic (IVD) technology to profile the circadian rhythm and explore its applications like time treatment in various indications, health prevention or to enhance athletic performance.

The InnoRampUp program aims to support technologically innovative startups in Hamburg with grants of up to €150,000 in the start-up phase. The program focuses on startups that have a realistic chance of achieving economic success and are led by a convincing team with an entrepreneurial spirit.

"We are thrilled to have been selected for funding by the InnoRampUp program," said Prof. Dr. Angela Relógio, CEO of TimeTeller®. "This support will allow us to continue developing our innovative technology and bring it to the market, ultimately helping to improve patient outcomes and advance science.”

This funding will enable TimeTeller® to make significant advances in the development of its IVD technology, positioning the company as a leader in the field of time-based measurements for clinical studies.